By Thomas Gryta, Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)-. (TEVA) doesn’t expect generic competition for its blockbuster multiple sclerosis treatment Copaxone before 2014, but the company warned that competition from oral MS drugs will likely pressure sales before that time.
The Copaxone battle is notable because it pits the world largest generics company, which has benefited from challenging the patents of other pharmaceutical companies, against generic competitors to protect the exclusivity of its own brand.
Momenta Pharmaceuticals Inc. (MNTA) and Mylan Inc. (MYL) have both filed to produce generic versions of Copaxone, a process that is likely to span years. The drug, one of the world’s best selling MS treatments with 2008 sales of $2.26 billion, is a key component of Teva’s business.
.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the “Stu’s Views and MS Related News”, weekly M.S. e-newsletter, then please take 20 seconds to register at: https://www.msviewsandnews.org . – Thank you
.
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================